Until recently the only discriminator was the cancer antigen
125 (CA 125) tumour marker.
Among the numerous novel biomarkers identified in an effort to overcome these weaknesses of PSA, prostate cancer antigen
3 (PCA3) is one of the most promising.
Molina, "Comparison of serum human epididymis protein 4 with cancer antigen
125 as a tumor marker in patients with malignant and nonmalignant diseases," Clinical Chemistry, vol.
Serum human chorionic gonadotropin (HCG), Cancer Antigen
125 (CA125), Cancer Antigen
19-9 (CA 19-9), alpha-fetoprotein (AFP) and lactate dehydogenase (LDH) were performed in 82%, 83%, 44%, 52%, 32%, respectively, and they were found to be elevated in 2%, 23%, 7%, 0% and 2% of the tested patients, respectively.
As described in detail below, we found that the CUZD1 ELISA did not recognize the CUZD1 protein, but instead it recognized another protein, mucin 16 (also known as CA125), which is an established cancer antigen
known to be increased in several cancer types (ovarian, pancreatic, and lung) (8).
* Prostate Cancer Antigen
3: Urine test approved in February 2012; indicated for men with elevated PSA levels and one or more previous negative biopsies to determine need for repeat biopsy; some evidence that PCA3 is useful in guiding decisions about first biopsy.
Ovarian cancer patients should have their cancer antigen
125 (CA-125) levels checked regularly.
Carcinoembryonic antigen (CEA), cancer antigen
(CA 199) and alpha-fetoprotein levels were normal.
Large-scale screening for ovarian cancer with a combination of transvaginal ultrasound and cancer antigen
125 is a feasible strategy that can accurately identify early cancers, a large U.K.
Urinary Bcl-2 was more accurate in identifying ovarian cancer than was cancer antigen
125 (CA125), which is currently considered to be the accepted standard for ovarian cancer detection, Dr.
In the study, all participants receiving the Cancer Vac immunotherapy generated immune responses that recognized the MUC 1 cancer antigen
, with the treatment being well tolerated by all patients.
OBI Pharma's candidate, OBI-999, works by specifically targeting cancer cells that are overexpressing the cancer antigen
SAN DIEGO -- There are "tantalizing" trends toward reduced ovarian cancer deaths with annual cancer antigen
125 screening in a U.K.
Serum cancer antigen
19-9 (CA19-9; an antigen that is elevated in approximately 80% of patients with pancreatic cancer) was also measured for comparison.
The need for validating the use of tumor markers was demonstrated in the recent evaluation of cancer antigen
125 (CA125) (2) measurements for monitoring patients with ovarian cancer (2).